Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

The Fall Issue of The Evidence Forum is Out

Read content related to the relevant issues facing companies along the path to approval and access

Explore Current Advanced Degree Internship Opportunities for Summer 2021

Be part of innovation at Evidera as you earn your master’s or doctorate by collaborating on initiatives at the forefront of clinical research

Learn More

Committed to Supporting Clients During the COVID-19 Pandemic

Access resources and information related to COVID-19 studies to discover how we are joining the COVID-19 fight

Learn More

Upcoming Webinar

Patient Preferences in Oncology: Status-Quo and Route to Success

Tuesday, April 27, 2021 | 10:00AM EDT

Blog Post

REMS: To Outsource or Not to Outsource?

Debbie Cheslow, Director, Risk Management Programs, discusses the pros and cons of outsourcing a REMS program versus developing one internally

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Oncology

The Cost-Effectiveness of Dacomitinib in First-Line Treatment of Advanced/Metastatic Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer (EGFR m NSCLC) in Sweden

Journal of Medical Economics
April 2021

Oncology

Epidemiological and Clinical Burden of EGFR Exon 20 Insertion in Advanced Non-Small Cell Lung Cancer: A Systematic Literature Review

PLoS One
April 2021

Neurology

Understanding the Migraine Treatment Landscape Prior to the Introduction of Calcitonin Gene‐Related Peptide Inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients Using Preventive Treatment (ATTAIN) Study

Headache
April 2021

What We Do

Real-World Evidence & Data Solutions

Obtain real-world evidence to optimize product value, effectiveness, safety, and market strategy by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Non-Interventional Studies

Robust design, epidemiologic and therapeutic area insights, advanced data analytics and precision study execution critical for study and program success.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Value & Development Consulting

End-to-end regulatory, clinical development, and value and access consulting services that span all phases of development.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

Regulators and payers are increasingly using data on patient preferences, and we support our clients in applying these methods to inform decision making across a product’s entire lifecycle.

Kevin Marsh, PhD, Executive Director, Commercial Strategy and New Product Development, Patient-Centered Research, Evidera

Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety during the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More